Despite the availability of various tools for measuring medication adherence, efficiently identifying non-adherence levels and reasons at the point of care remains challenging. Existing tools often lack the ease of use needed for practical clinical application. This study aimed to develop and validate a user-friendly tool to provide healthcare professionals with a concise yet comprehensive means of identifying adherence behaviors. The methodology consisted of two phases: tool items were first developed using the nominal group technique with healthcare professionals, followed by a cross-sectional pilot study involving community-dwelling adults in Croatia. Validation analysis indicated acceptable face and content validity and satisfactory criterion validity, with Attitudes towards meDication adHErence self-Reported questionnairE (ADHERE-7) scores correlating with both the self-reported five-item Medication Adherence Report Scale (MARS-5 tool) (ρ = 0.765; p < 0.001) and an objective measure of the proportion of days covered (PDC) from pharmacy prescription claims data (G = 0.586; p = 0.015). Construct validity revealed three factors: Aversion, Comfort, and Practical Non-Adherence, with Cronbach’s alpha values of 0.617 for Aversion and 0.714 for Comfort Non-Adherence. The mean total score for ADHERE-7 was 26.27 ± 2.41 (range 17 to 28). This robust validation process confirms the ADHERE-7 tool as a reliable instrument for assessing medication adherence, addressing aversion, comfort, practical issues, and both intentional and unintentional nonadherence.
L -Met-enkephalin is a neuropeptide known to exert protective effects in various experimental models of autoimmune and inflammatory diseases. These effects are mediated through opioid receptors and can be abolished by the opioid receptor antagonist naltrexone. Investigation of peptide enantiomerism and the incorporation of d-amino acids are crucial for designing novel peptides with altered structural and biological properties compared with their native l-forms. Since no data are currently available on the properties or biological activity of the d-Met-enkephalin enantiomer, we evaluated its hepatoprotective potential in a mouse model of acetaminophen-induced hepatotoxicity. Male CBA mice were treated with d-Met-enkephalin, and hepatoprotection was assessed by measuring plasma alanine aminotransferase (ALT) and aspartate amino-transferase (AST) activities, along with histological liver necrosis scores. The peptide’s secondary structure and antisense peptide binding were analysed using circular dichroism and fluorescence spectroscopy, respectively. d -Met-enkephalin demonstrated dose-dependent hepatoprotective effects within the range of 0.5–20 mg kg–1, with maximal protection observed at 5 mg kg –1 , a dose comparable to that of the l-enantiomer (7.5 mg kg –1 ). This preservation of biological activity may be attributed to the presence of the achiral amino acid glycine at positions 2 and 3, which maintains the functional conformation of the d-enantiomer. The role of opioid receptor involvement was further examined through direct receptor blockade using naltrexone and indirect inhibition with the antisense peptide IPPKY.
Antibiotic resistance is a growing global health threat, with patient non-adherence to prescribed antibiotic regimens representing an important contributing factor. This prospective interventional study investigated the impact of clinical pharmacist counselling at hospital discharge on adherence to oral antibiotic therapy. The study was conducted at the Department of Nephrology and Endocrinology, General Hospital “Dr. Tomislav Bardek”, Koprivnica, between March 2022 and July 2025. A total of 98 participants aged ≥18 years who were prescribed oral antibiotics at discharge were randomised into intervention (counselling) and non-intervention groups. Baseline socio-demographic and clinical data were collected, and adherence was assessed following treatment completion using a structured questionnaire developed by the authors. Of the 98 participants, 94 were included in the final analysis. Non-adherence was significantly lower in the intervention group, compared to the non-intervention group (2.1 % vs. 36.2 %, p < 0.001). Urinary tract infections represented the most common indication for antibiotic therapy, with ciprofloxacin and amoxicillin-clavulanic acid being the most frequently prescribed medicines. This study demonstrates that pharmacist-led discharge counselling markedly improves adherence to short-term antibiotic therapy. These findings provide preliminary evidence supporting integration of clinical pharmacists into hospital discharge processes to promote rational antibiotic use and combat antimicrobial resistance.
Optimising medication adherence is essential for effective heart failure (HF) management, yet nonadherence remains common, particularly among hospitalised and advanced-stage patients. This study evaluated the internal consistency reliability and score association of the Medication Adherence Report Scales, MARS-5 and MARS-10, self-report questionnaires in clinical pharmacist-led adherence assessments in hospitalised HF patients. Tools were administered during structured pharmacist-led interviews. To complement quantitative findings, four clinical cases were presented to illustrate the clinical relevance of adherence assessment in real--world HF management. Results showed a strong association between MARS-5 and MARS-10 ( n = 70) responses (unweighted Cohen’s kappa 0.820 (95 % CI 0.683–0.957; p < 0.001) for categorizing patients as nonadherent or adherent and Pearson’s r coefficient of 0.899 (95 % CI 0.847–1.000; p < 0.001) for continuous score correlation), supporting score association and flexible use in clinical settings, with MARS-5 reliably identifying nonadherence (defined as score < 20 for MARS-5 and ≤ 8 for MARS-10), with potentially reduced respondent burden due to fewer items. Serious clinical complications were documented in nonadherent patients (41.43 % by MARS-5 and 35.71 % by MARS-10), illustrated through selected cases including stent thrombosis, embolic stroke, graft dysfunction, and deterioration in glycaemic control. These findings indicate the potential of MARS-5 as a practical, time-efficient tool for routine adherence assessment in acute settings. Case analyses underscore the critical role of the clinical pharmacist in proactively identifying nonadherence and enabling timely, targeted interventions to mitigate risk and improve patient outcomes in HF care.